ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

BridgeBio licenses compounds from NeuroVive and launches Fortify Therapeutics

by Ryan Cross
June 24, 2018 | APPEARED IN VOLUME 96, ISSUE 26

Genetic disease company BridgeBio Pharma has launched a subsidiary called Fortify Therapeutics with an initial $20 million in funds and about $40 million more in potential future payments. Fortify will develop a set of succinate prodrug compounds that BridgeBio licensed from NeuroVive to treat a vision loss disease called Leber hereditary optic neuropathy. Fortify is the third subsidiary that BridgeBio has announced in just over a week.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment